Ovid Therapeutics Inc.OVIDNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-9.47%
↓ 137% below average
Average (39q)
25.46%
Historical baseline
Range
High:683.87%
Low:-80.58%
Volatility
3002.1%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -9.47% |
| Q2 2025 | -2.91% |
| Q1 2025 | 12.43% |
| Q4 2024 | -24.60% |
| Q3 2024 | -37.57% |
| Q2 2024 | 21.02% |
| Q1 2024 | -2.30% |
| Q4 2023 | 99.55% |
| Q3 2023 | -11.10% |
| Q2 2023 | -9.31% |
| Q1 2023 | 19.06% |
| Q4 2022 | 7.20% |
| Q3 2022 | -14.28% |
| Q2 2022 | -22.80% |
| Q1 2022 | -56.65% |
| Q4 2021 | 267.38% |
| Q3 2021 | -36.00% |
| Q2 2021 | -52.71% |
| Q1 2021 | -0.21% |
| Q4 2020 | 2.57% |
| Q3 2020 | -0.98% |
| Q2 2020 | 9.62% |
| Q1 2020 | 20.82% |
| Q4 2019 | 4.37% |
| Q3 2019 | 27.21% |
| Q2 2019 | -13.95% |
| Q1 2019 | 22.88% |
| Q4 2018 | -7.50% |
| Q3 2018 | 10.26% |
| Q2 2018 | -0.25% |
| Q1 2018 | 26.24% |
| Q4 2017 | 13.79% |
| Q3 2017 | -2.89% |
| Q2 2017 | -80.58% |
| Q1 2017 | 683.87% |
| Q4 2016 | 47.88% |
| Q3 2016 | 52.46% |
| Q2 2016 | 57.07% |
| Q1 2016 | -1.05% |
| Q4 2015 | 0.00% |